Corcept Therapeutics Stock Hits 52‑Week High Amid Analyst Upgrades

Corcept Therapeutics' shares surged to a new 52‑week high, trading around $95.50 after reaching $95.68 intraday. Analysts upgraded their outlook, with Canaccord Genuity raising its price target to $135 and HC Wainwright to $95, while the average target across analysts sits at $88.83 and the consensus rating is a moderate buy.

The company's CFO, Mokari Atabak, exercised a cashless option and sold 40,000 shares on July 15, 2026 under a pre‑established Rule 10b5‑1 plan at an average price of $87.71. He retained 16,130 shares and holds approximately 180,000 derivative securities, keeping substantial economic exposure to the firm.

Corcept reported quarterly earnings of a $0.30 loss per share, missing consensus estimates of a $0.11 loss, and posted revenue of $164.9 million, below analysts' $185.8 million expectation. The biotechnology firm has a market capitalization of roughly $10‑11 billion.